WallStSmart
STE

STERIS plc

NYSE: STE · HEALTHCARE · MEDICAL DEVICES

$212.65
-3.23% today

Updated 2026-04-29

Market cap
$20.87B
P/E ratio
29.66
P/S ratio
3.58x
EPS (TTM)
$7.17
Dividend yield
1.09%
52W range
$210 – $269
Volume
0.8M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

STERIS plc (STE) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$212.65
Consensus
$275.20
+29.41%
2030 Target
$967.87
+355.15%
DCF
$193.71
-25.69% MoS
6 analysts:
4 Buy2 Hold1 Sell

Management guidance

STERIS management provided FY2026 EPS guidance of $10.15–$10.30 (midpoint $10.225), implying revenue growth aligned with analyst consensus of ~9.9% for FY2026. No specific revenue dollar targets or multi-year guidance statements were identified in CEO commentary, so projections rely on analyst consensus and historical trajectory.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$1,605.78
$7.9B Rev × 20x P/S
Base case (2030)
$967.87
$7.9B Rev × 12x P/S
Bear case (2030)
$637.91
$7.9B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$4.5B$5.1B$5.5B$6.0B$6.4B$6.8B$7.3B$7.9B
Revenue growth—13.3%6.2%9.9%6.3%7.4%7.3%7.2%
EPS—$8.83$7.34$10.30$11.21$12.15$13.25$14.50
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$747.90$791.89$835.89$901.88$967.87

Catalysts & risks

Growth catalysts
+ Strong institutional ownership (94.69%) and recent accumulation by hedge funds (Holocene +977.7%, Carderock +24.7%) signal conviction in growth
+ Healthcare segment margin recovery and resilient pricing power in sterilization/endoscopy solutions despite tariff headwinds
+ Dividend growth trajectory (9.68% 3Y CAGR, 8.99% 5Y CAGR) suggests management confidence in sustained earnings expansion
Key risks
- Tariff and supply chain pressures mentioned as headwinds in recent earnings; potential margin compression if input costs accelerate
- Technical death cross and YTD underperformance (-13.23%) suggest near-term momentum risk despite fundamental strength
- Healthcare sector macro headwinds and regulatory uncertainty could pressure volumes or pricing in key segments

Methodology

STERIS plc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 6 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.